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Abstract
Background: Protein tyrosine phosphatase receptor delta (PTPRD) is a member of a large family of protein tyrosine
phosphatases which negatively regulate tyrosine phosphorylation. Neuroblastoma is a major childhood cancer
arising from precursor cells of the sympathetic nervous system which is known to acquire deletions and alterations
in the expression patterns of PTPRD, indicating a potential tumor suppressor function for this gene. The molecular
mechanism, however, by which PTPRD renders a tumor suppressor effect in neuroblastoma is unknown.
Results: As a molecular mechanism, we demonstrate that PTPRD interacts with aurora kinase A (AURKA), an
oncogenic protein that is over-expressed in multiple forms of cancer, including neuroblastoma. Ectopic up-
regulation of PTPRD in neuroblastoma dephosphorylates tyrosine residues in AURKA resulting in a destabilization of
this protein culminating in interfering with one of AURKA’s primary functions in neuroblastoma, the stabilization of
MYCN protein, the gene of which is amplified in approximately 25 to 30% of high risk neuroblastoma.
Conclusions: PTPRD has a tumor suppressor function in neuroblastoma through AURKA dephosphorylation and
destabilization and a downstream destabilization of MYCN protein, representing a novel mechanism for the
function of PTPRD in neuroblastoma.
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Background
Protein tyrosine phosphatase receptor delta (PTPRD) is
an important regulator of axon growth and guidance
and is highly expressed in the central nervous system
where it functions as a transmembrane homophilic neu-
ronal cell adhesion molecule [1]. PTPRD undergoes a
high frequency of hemizygous/homozygous deletions in
multiple forms of cancer, which are often intragenic in
nature, indicating a potential tumor suppressor function
[2-8]. Additional mechanisms leading to PTPRD inacti-
vation include promoter region hypermethylation, point
mutations and aberrant splicing [6,9-12].
Neuroblastoma is derived from primitive cells of the
sympathetic nervous system, and is the most common
extracranial solid tumor in children accounting for 15%
of all childhood cancer deaths [13]. These tumors are
particularly noted for extensive heterogeneity in clinical
behaviour, ranging from spontaneous regression to
aggressive clinical course and death from disease. Nota-
bly, amplification of the MYCN transcription factor is
one of the most powerful adverse prognostic factors in
neuroblastoma [14] and we have previously demon-
strated that PTPRD is expressed at significantly lower
levels in MYCN amplified neuroblastoma relative to
non-MYCN amplified tumors [10]. In addition, PTPRD
mRNA expression is higher in normal adrenal fetal neu-
roblasts, the cell of origin of neuroblastoma, relative to
unfavourable neuroblastoma tumors, indicating that
PTPRD down-regulation might be an important step in
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the development of these tumors [7,10]. Multiple
mechanisms appear to exist for the down-regulation of
PTPRD in neuroblastoma, including intragenic microde-
letions which can include coding sequence, or in some
instances be restricted to non-coding exons of an
extended 5’ UTR [5]. Aberrant splicing of the 5’ UTR
also has been noted in neuroblastoma cell lines and pri-
mary tumors, which could potentially cause destabiliza-
tion of the mRNA sequence [10].
In this report, we demonstrate for the first time that
experimental up-regulation of PTPRD in neuroblastoma
cell lines significantly decreases cell growth and
increases apoptosis. Moreover, we identify aurora kinase
A, a serine/threonine kinase oncogene that is up-regu-
lated in many forms of cancer, including high risk neu-
roblastoma [15], as an interaction partner of PTPRD.
We further demonstrate that PTPRD has a tumor sup-
pressor function in neuroblastoma through dephosphor-
ylating and destabilizing AURKA, leading to a
downstream decrease of MYCN protein. Our findings
represent a novel mechanism of action for the function
of PTPRD in neuroblastoma.
Results
PTPRD functions as a tumor suppressor in neuroblastoma
In order to further examine the possibility that PTPRD
acts as a tumor suppressor gene in neuroblastoma, we
initially analyzed the levels of PTPRD mRNA transcripts
in a set of 88 neuroblastoma tumors using the R2:
microarray analysis and visualization platform (http://r2.
amc.nl) (University of Amsterdam). Lower than median
PTPRD mRNA levels were significantly associated with
both poor relapse free and overall patient survival, con-
sistent with PTPRD having a tumor suppressor function
(Figure 1A and 1B).
We then sought to determine the effects of PTPRD
over-expression in neuroblastoma cell lines that have
only minimally detectable PTPRD mRNA transcripts.
Kelly cells (MYCN amplified) have a homozygous dele-
tion in the PTPRD 5’ UTR [5], while SHSY-5Y (MYCN
non-amplified) has a 5’ UTR that was generated by exon
skipping [10]. Although there is no evidence for deletion
or aberrant splicing of PTPRD in CHP212 (MYCN
amplified), endogenous mRNA transcripts are neverthe-
less at very low levels. These three cell lines were trans-
fected with a wild type PTPRD V5-tagged cDNA clone
[6] to determine the impact of over-expression on cell
growth. Ectopic expression of PTPRD at mRNA and
protein level was validated by TaqMan qPCR and by
Western blot analysis (for a V5 epitope tag) (Additional
File 1). Ectopic up-regulation of PTPRD resulted in a
significant decline in cell growth in all three cell lines
(Figure 2A-C). To determine if the phosphatase activity
of PTPRD is required to have anti-proliferative effects
Figure 1 Kaplan Meier survival curves demonstrating the relationship between patient survival and PTPRD gene expression using the
R2: microarray analysis and visualization platform (http://r2.amc.nl). (A) is relapse free survival and (B) is overall survival where low
expression is < median (n = 44 (tumors) and high expression is > median (n = 44 tumors).
Meehan et al. Molecular Cancer 2012, 11:6
http://www.molecular-cancer.com/content/11/1/6
Page 2 of 9
on cell lines, a mutant form of PTPRD containing a can-
cer specific mutation, Q1481X, that results in a trun-
cated protein product lacking a functional C-terminal
phosphatase domain, was transfected into Kelly cells.
Over-expression of this PTPRD mutant did not lead to a
significant decrease in cell growth compared to empty
vector transfected cells (Figure 2D), indicating that a
functional phosphatase domain is required. FACS analy-
sis of Kelly cells transfected with either wild type
PTPRD or empty vector, followed by staining with pro-
pidium iodide and staining for Annexin V, revealed that
PTPRD up-regulation resulted in a median 1.7 fold
increase in apoptosis relative to empty vector control
(Figure 2E, F).
Identification of proteins that interact with PTPRD
Taken together, all available evidence indicates that
PTPRD is a neuroblastoma tumor suppressor, but the
molecular mechanism(s) is unknown, as only a small
number of PTPRD interacting partners have been iden-
tified. PTPRD is known to interact with the metastasis
suppressor protein 1 (MTSS1), liprin-alpha 1 (LAR), and
Figure 2 Ectopic over-expression of wild type PTPRD suppresses the growth of human neuroblastoma cell lines by inducing cell
apoptosis. (A) SHSY5Y (B) Kelly and (C) CHP-212 cells were transfected with PTPRD cDNA or empty vector (pcDNA3.1-V5) and were analysed by
a Cyquant assay at 24, 48 and 72 h. All graphs report mean ± S.E.M., n = 3, ** p < 0.01, *** p < 0.001. (D) Kelly cells transfected with either
empty vector or an expression plasmid containing PTPRD with a mutated phosphatase domain. PTPRD induced apoptosis was demonstrated by
FACS analysis of annexin-V staining. Kelly cells were transfected with empty vector (E) or PTPRD cDNA (F). Cells were harvested 72 h post
transfection. PI staining of DNA represents necrotic cells (upper left quadrant). Annexin V staining indicates cells that are early apoptotic (bottom
right quadrant). Double stained cells (upper right quadrant) indicate cells in late apoptosis. Percentages of cells in each quadrant are shown.
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signal transducer and activator of transcription 3
(STAT3) [6,16,17]. In order to discover new potential
substrates for PTPRD in the context of neuroblastoma,
we used a commercially available protein-protein inter-
action array containing 9,400 proteins. A biotinylated
PTPRD protein was used to probe the protein microar-
ray to detect potential interaction partners. This experi-
ment was conducted in duplicate (biological replicates
as two different biotinylated PTPRD baits were used).
The consensus interacting proteins with above-back-
ground signal are listed in Table 1.
One of the top scoring proteins on the PTPRD inter-
action arrays was aurora kinase A (AURKA), a serine/
threonine kinase that is involved in microtubule forma-
tion and stabilization at the spindle pole during chromo-
some segregation [18]. In neuroblastoma, high AURKA
expression is associated with poor patient survival [15],
so that the interaction of a tumor suppressor with
AURKA was of immediate interest. In order to confirm
an in vivo interaction between PTPRD and AURKA in
neuroblastoma, protein extract isolated from Kelly cells
transfected with either the V5-tagged PTPRD cDNA or
empty vector was immunoprecipitated with a V5 epitope
antibody. As illustrated in Figure 3A, western blotting
demonstrated that V5-tagged PTPRD was
immunoprecipitated from cells, with a clear band of
approximately 85 kDa being detected compared with
empty vector control. The PTPRD pro-protein (220
kDa) is cleaved intracellularly into two subunits of 150
kDa (E-subunit) and 85 kDa (P-subunit) [19]. This pro-
cess is called “ectodomain shedding” and affects a num-
ber of transmembrane proteins. The 150-kDa E-subunit
is predicted to contain the three Ig-like and eight FN-
III-like domains, whereas the 85-kDa P-subunit contains
a short ectodomain segment, the transmembrane pep-
tide, and the intracellular PTPase domains and is
expressed in the membrane of the cell. The 150 kDa
band is not visualized because it has lost the V5 epitope
tag. Western blot probed with AURKA antibody indi-
cates that AURKA co-immunoprecipitates with the V5
epitope pulled down with the V5 antibody, confirming a
PTPRD-AURKA interaction in vivo (Figure 3B).
PTPRD destabilizes AURKA by dephosphorylating tyrosine
sites
Having confirmed a PTPRD-AURKA interaction, we
next investigated whether AURKA is a potential sub-
strate for PTPRD. Within the catalytic domain of
AURKA, there are a number of conserved tyrosine
phosphorylation sites (Y148, Y199, Y197, Y212) [20]).
Table 1 Protein Interaction Array Results
Gene ID Array ID Z-score 1A* Z-score 1B Z-score 2A Z-score 2B Mean Score
SLAIN2 BC031691.2 15.6862 14.84417 26.53102 26.53143 20.898205
AURKA PV3612 17.81632 17.54567 23.21736 21.82452 20.1009675
NEK1 PV4202 11.32571 10.6591 26.53388 26.53388 18.7631425
PLK1 PV3501 10.43356 7.98767 26.28537 24.45825 17.2912125
EPHA8 PV3844 13.1952 11.49612 21.98299 21.87788 17.1380475
TBK1 PV3504 12.278 11.42595 21.61471 18.89013 16.0521975
CSNK1D PV3665 6.59933 4.8401 23.86103 21.60616 14.226655
CSNK1E PV3500 4.19855 3.59711 15.00776 14.78818 9.3979
MARK2 PV3878 5.18092 4.76492 11.28101 13.46825 8.673775
STK22B PV3622 4.70477 4.58448 9.74924 10.31917 7.339415
SMTNL2 NM_198501.1 8.20319 7.9576 6.70486 6.47999 7.33641
PAK6 PV3502 6.12319 4.86015 9.65432 8.0142 7.162965
NEK2 PV3360 3.79759 3.28135 10.46746 10.817 7.09085
DDX17 NM_030881.2 11.17033 10.22806 3.26491 3.22825 6.9728875
NEK6 PV3353 7.72705 7.69697 5.83062 5.50919 6.6909575
ABLIM1 BC002448.2 7.49649 4.08829 7.04747 7.37379 6.50151
SCEL BC020726.1 4.70978 2.7651 10.60149 5.45623 5.88315
BMX PV3371 5.37138 5.07566 5.66807 4.98611 5.275305
MATK PV3370 3.42168 3.27633 6.37244 7.68829 5.189685
IRS1 BC053895 5.80241 5.78237 3.98394 2.59843 4.5417875
DDX54 BC001132.1 3.27132 2.99065 3.27469 3.16062 3.17432
*1A and 1B are technical replicates using the same protein bait. 2A and 2B are technical replicates using a second bait are therefore biological replicates of 1A
and 1B.
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Immunoprecipitation of tyrosine phosphorylated pro-
teins with a pan-phosphotyrosine agarose conjugate and
subsequent western blotting with an AURKA antibody
revealed an abolishment of AURKA tyrosine phosphory-
lation in PTPRD cDNA transfected cells compared to
phosphatase dead mutant or empty vector control trans-
fectants, confirming the mechanism of action of PTPRD
(Figure 3C). In addition to deactivating AURKA, ectopic
over-expression of PTPRD also leads to a decrease in
protein stability of AURKA. After 4 hours of cyclohexi-
mide treatment, there is a significant difference in the
decay of AURKA in the PTPRD transfected cells com-
pared to empty vector (EV) or phosphatase dead mutant
(Figure 3D, E). qPCR analysis of AURKA mRNA at 48
hours post PTPRD transfection indicated no significant
change relative to negative control, confirming that the
AURKA decrease is post-transcriptional (Additional File
2A).
Figure 3 V5 immunoprecipitation experiments and western blots. (A) Kelly cells were transfected with PTPRD cDNA or empty vector
(pcDNA3.1-V5). V5 Immunoprecipitates were subjected to western blot with an AURKA antibody in order to confirm in vivo association of
AURKA and PTPRD. (B) Western blot of the same immunoprecipitates with a V5 antibody demonstrates the pull down of V5 PTPRD. (C) Kelly
cells were transfected with PTPRD cDNA, empty vector or PTPRD mutant (Q1481X). Post pan-phosphotyrosine immunoprecipitation (pY) and
western blotting with AURKA reveals the phosphorylation status of AURKA in these transfectants. Immunoprecipitation of the V5 tag and
subsequent western blotting with V5 confirms upregulation of V5-PTPRD (D) Ectopic up-regulation of PTPRD results in destabilization of AURKA.
Kelly cells were transfected with PTPRD cDNA, empty vector or the phosphatase dead PTPRD mutant Q14811. Lysates were harvested 72 hours
post transfection and treated at 0, 1, 2, 3, 4 and 6 hours with cycloheximide and then subjected to western blot analysis with an AURKA
antibody. Alpha tubulin was used as a loading control. (E) The graph shows quantitative densitometry of the protein expression of AURKA (n =
2) following normalization with the endogenous control. (F) Ectopic up-regulation of PTPRD results in a decrease in protein levels of AURKA. and
MYCN. Increasing concentrations of PTPRD cDNA were transfected into Kelly cells. Lysates were harvested 72 hours post transfection and
subjected to western blot analysis with V5, AURKA and MYCN antibodies. Alpha tubulin was used as a loading control
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A critical function of AURKA in neuroblastoma is to
regulate MYCN protein stability by sequestering MYCN
from ubiquitin-mediated proteolytic degradation
mediated by the FBXW7 ubiquitin ligase [21], leading us
to hypothesize that a down-stream effect of ectopic
over-expression PTPRD in neuroblastoma cells would
be the destabilization of MYCN. As illustrated in Figure
3F, MYCN protein levels are also decreasing as a conse-
quence of PTPRD ectopic over-expression. The decrease
in MYCN protein is due to a post-transcriptional
mechanism, as there is no change in MYCN mRNA
(Additional File 2B).
Discussion
In this report we demonstrate a novel in vivo interaction
between the tumor suppressor PTPRD and the onco-
genic AURKA protein in neuroblastoma. Furthermore,
to our best knowledge, this is the first report to demon-
strate dephosphorylation of tyrosine residues in AURKA
leading to its subsequent destabilization. The identifica-
tion of AURKA as a novel target of PTPRD mediated
dephosphorylation adds to a growing list of substrates
for this tumor suppressor. Activity of AURKA is also
regulated by phosphorylation of Thr288 in a cell cycle
dependent manner [22]. Constitutive phosphorylation
on Ser51 of AURKA has also been shown to be asso-
ciated with its over-expression and protein stabilization,
preventing protein degradation mediated by the ubiqui-
tin-proteasome system [23] and it is likely that constitu-
tive phosphorylation of tyrosine residues in AURKA also
prevent its degradation. AURKA destabilization also has
the down-stream effect of destabilizing MYCN, consis-
tent with prior findings by Otto et al. [21]. Thus,
PTPRD is likely to have a tumor suppressor function in
any type of cancer with MYCN amplification, including
other pediatric cancers such as medulloblastoma and
rhabdomyosarcoma, or in adult tumors that are depen-
dent on high AURKA levels.
MYCN directly up-regulates AURKA by binding to its
promoter region, forming an auto regulatory feedback
loop [21]. As previously mentioned, PTPRD expression
is significantly lower in MYCN amplified tumors relative
to non-MYCN amplified tumors [10], indicating that
MYCN might be directly repressing PTPRD in order to
maintain AURKA levels. However, analysis of a pre-
viously published data set on MYCN binding sites in
neuroblastoma cell lines indicated that MYCN does not
bind to the PTPRD promoter region [24,25], revealing
that down-regulation of PTPRD in MYCN amplified
tumors is an indirect effect.
Along with AURKA, a number of other proteins
scored highly in our protein-protein interaction arrays,
including SLAIN2, and two serine/threonine kinases,
NEK2 and PLK1.
SLAIN2 has recently been shown to play an important
role in the microtubule complex by controlling microtu-
bule dynamics and organization [26]. NEK2 is an inte-
gral component of the mitotic spindle-assembly
checkpoint which is necessary for proper chromosome
segregation during metaphase-anaphase transition [27],
while PLK1 is an early trigger for G2/M transition [28].
Intriguingly, one of the primary functions of AURKA is
the activation of PLK1 by direct phosphorylation of
Thr210 [29], and high expression of PLK1 is also signifi-
cantly associated with high-risk neuroblastoma and
unfavourable patient outcome [30]. Inhibition of PLK1
protein has an anti-proliferative effect on neuroblastoma
cell proliferation [30]. Although the interaction of
PTPRD with these proteins requires validation, it seems
likely that over-expression of PTPRD should have a
pleiotrophic tumor suppressor effect by associating with,
and dephosphorylating a number of interacting partners.
The recent development of AURKA inhibitors, along
with impressive results in pre-clinical models of pedia-
tric cancer, indicate that AURKA could be a therapeutic
target of great value in the treatment of neuroblastoma
[31,32]. PTPRD, as a natural antagonist of AURKA,
might be of therapeutic value in cancers where its inac-
tivation is epigentically reversible, such as in instances
of promoter region hypermethylation.
Conclusions
Over-expression of PTPRD in neuroblastoma cell lines
results in decreased cell viability through the activation
of apoptosis. We further demonstrate a novel PTPRD-
AURKA protein interaction, and that PTPRD over-
expression results in the dephosphorylation and the
destabilization of AURKA, along with a down-stream
destabilization of MYCN protein. These findings, taken
together, indicate a novel mechanism of action for
PTPRD as a neuroblastoma tumor suppressor through
the inhibition of these important oncogene products.
Methods
Cell Culture, In Vitro Growth and Apoptosis Assays
SHSY-5Y and CHP-212 neuroblastoma cell lines were
obtained from the American Type Culture Collection,
while Kelly was obtained from European Collection of
Animal Cell Cultures. All cell lines were validated for
the presence of previously published genomic imbal-
ances using aCGH. Culture media was supplemented
with 10% FBS.
Cells were transfected with 2 μg PTPRD cDNA, empty
vector (pcDNA3.1-V5) or phosphatase dead mutant
PTPRD (Q14811) using lipofectamine 2000 reagent
according to
the manufacturer’s instructions (Invitrogen, Carlsbad,
CA) and were analysed by a Cyquant assay (Invitrogen)
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at 24, 48 and 72 h. PTPRD induced apoptosis was
demonstrated by FACS analysis of annexin-V staining.
Kelly cells were transfected with empty vector or
PTPRD cDNA. Cells were harvested 72 h post transfec-
tion and apoptosis was quantified using the FITC
Annexin-V Apoptosis Detection Kit I (BD Pharmingen,
San Diego, CA, USA). Experiments were performed in
triplicate to quantify apoptosis by phosphatidylserine
(PS) externalization.
Immunoprecipitation experiments
Kelly cells (80-90% confluence) were transfected with 2
μg PTPRD cDNA or empty vector (pcDNA3.1-V5) in
100 mm dishes. After 24 h transfection, cells were incu-
bated in a RIPA buffer (Sigma-Aldrich, Arklow) contain-
ing complete protease inhibitor mixture. The lysates
were cleared by centrifugation for 20 min at 14,000 × g
and then subjected to immunoprecipitation with either
anti-V5 agarose affinity beads (Sigma-Aldrich) for co-IP
experiments or 4 G10® Platinum, anti-phosphotyrosine
agarose conjugate (Millipore) for pan-tyrosine IP experi-
ments, and then incubated at 4 C for 2 h. The beads
were washed five times with RIPA buffer, incubated in
laemmli sample buffer and heated to 95 C for five mins.
Resultant samples were separated by SDS-PAGE and
were analysed by western blotting.
Western blotting
Cells were washed with PBS and lysed at 4 C for 20 min
using RIPA buffer containg phosphatase and protease
inhibitors. Lysates were centrifuged for 20 min at 14,000
× g and resultant protein extracts were separated by
SDS-PAGE and blotted onto PVDF membranes. Antibo-
dies used were as follows: anti-V5 (Invitrogen), anti-
AURKA (Sigma), anti-MYCN (Santa Cruz) and anti-
alpha tubulin (Abcam). Secondary antibodies were
horseradish peroxidise-conjugated rabbit anti-mouse
(Abcam) or goat anti-rabbit (Cell Signaling Technology).
Reactive proteins were visualized by chemiluminescence
with ECL (Thermo).
PTPRD Interaction arrays
Purified PTPRD protein (99% pure, mass spectrum veri-
fied) (Clone ID 8613c5BCt10p1, protein sequence 1201-
1495) was biotinylated and quantitated in duplicate
using the Invitrogen FluoReporter® Biotin Quantitation
Assay Kit. The array control protein (biotinylated cal-
modulin kinase) supplied as part of the Invitrogen pro-
tein interaction kit was used to probe the Protoarray®
control protein microarray to validate assay conditions.
Biotinylated PTPRD baits (two biological replicates)
were then used to probe the Invitrogen ProtoArray®
Protein Microarray Kit for biotinylated proteins Version
4 in order to detect potential interaction partners. The
results were analyzed using the Protoarray prospector®
package. The consensus hits (hits that are above the
back ground signal in both the experiments) along with
their Z-scores are listed in Table 1. A Z-Score indicates
how far and in what direction the value of an individual
data point in a population falls from the mean in units
of standard deviations. ProtoArray® Prospector collects
all the signals from the proteins on a microarray, calcu-
lates the mean value and standard deviation, and then
calculates a Z-Score corresponding to the signal from
each feature.
Cycloheximide half-life experiments
Kelly cells (80-90% confluence) were transfected with 2
μg PTPRD cDNA, empty vector (pcDNA3.1-V5) or
PTPRD mutant (Q1481X) in 100 mm dishes. After 72 h
transfection, cells were incubated in a RIPA buffer
(Sigma-Aldrich, Arklow) containing complete protease
inhibitor mixture. Cells were treated with 1 μl of a 20
mg/ml stock solution of cycloheximide (Sigma-Aldrich)
5 min prior to starting the indicated time course, and
cells were collected at the indicated points. Quantifica-
tion of western blots was performed by densitometry
using GelEval (FrogDance Software). Normalization for
loading differences was achieved by dividing the densito-
metry values for individual bands by the densitometry
values for alpha-tubulin in the same lane.
Additional material
Additional File 1: Expression of PTPRD (A) mRNA and (B) protein
following transfection of Kelly cells with increasing concentrations
of PTPRD cDNA. mRNA was extracted at 24 hours and qPCR was
performed. Lysates were harvested at 48 h and subjected to SDS PAGE
and western blot analysis with a monoclonal antibody to the V5 epitope
tag or alpha tubulin. All experiments were performed in triplicate.
Additional File 2: (A) Expression of AURKA mRNA 48 hours post
PTPRD expression. Either 1 μg of PTPRD or empty vector (E.V.) were
transfected into Kelly cells. mRNA was extracted at 48 hours and qPCR
was performed. The figure is representative of four independent
experiments and E.V. is set as 1.0. (B) Expression of MYCN mRNA 48
hours post PTPRD expression. Either 1 μg of PTPRD or empty vector (E.V.)
were transfected into Kelly cells. mRNA was extracted at 48 hours and
qPCR was performed. The figure is representative of four independent
experiments and E.V. is set as 1.0.
Abbreviations
AURKA: aurora kinase A; PTPRD: Protein Tyrosine Phosphatase Receptor
Delta; IP: immunoprecipitation
Acknowledgements
This work was supported in part by the Association of International Cancer
Research (07-0033) and the Children’s Medical and Research Foundation. We
acknowledge the New York SGX Research Center for Structural Genomics
(NYSGXRC, NIGMS Grant U54 GM074945) for providing samples of purified
PTPRD protein.
Meehan et al. Molecular Cancer 2012, 11:6
http://www.molecular-cancer.com/content/11/1/6
Page 7 of 9
Author details
1Department of Molecular and Cellular Therapeutics, Royal College of
Surgeons in Ireland, Dublin 2, Dublin, Ireland. 2National Children’s Research
Centre, Our Lady’s Children’s Hospital, Dublin 12, Dublin, Ireland. 3Centre for
Human Proteomics, Royal College of Surgeons in Ireland, Dublin 2, Dublin,
Ireland. 4Department of Radiation Oncology, Memorial Sloan-Kettering
Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
Authors’ contributions
MM, LP, EL, NF, JR conceived and performed experiments and assisted with
writing the manuscript. CAJ, NM, DM and RLS conceived experiments and
assisted with writing the manuscript. BO, AF and TAC provided unique
research materials. All authors read and approved the final manuscript
Competing interests
The authors declare that they have no competing interests.
Received: 7 September 2011 Accepted: 5 February 2012
Published: 5 February 2012
References
1. Wang J, Bixby JL: Receptor tyrosine phosphatase-delta is a homophilic,
neurite-promoting cell adhesion molecular for CNS neurons. Mol Cell
Neurosci 1999, 14:370-384.
2. Giefing M, Zemke N, Brauze D, Kostrzewska-Poczekaj M, Luczak M,
Szaumkessel M, Pelinska K, Kiwerska K, Tonnies H, Grenman R, et al: High
resolution ArrayCGH and expression profiling identifies PTPRD and
PCDH17/PCH68 as tumor suppressor gene candidates in laryngeal
squamous cell carcinoma. Genes Chromosomes Cancer 2011, 50:154-166.
3. Purdie KJ, Lambert SR, Teh MT, Chaplin T, Molloy G, Raghavan M, Kelsell DP,
Leigh IM, Harwood CA, Proby CM, Young BD: Allelic imbalances and
microdeletions affecting the PTPRD gene in cutaneous squamous cell
carcinomas detected using single nucleotide polymorphism microarray
analysis. Genes Chromosomes Cancer 2007, 46:661-669.
4. Sato M, Takahashi K, Nagayama K, Arai Y, Ito N, Okada M, Minna JD,
Yokota J, Kohno T: Identification of chromosome arm 9p as the most
frequent target of homozygous deletions in lung cancer. Genes
Chromosomes Cancer 2005, 44:405-414.
5. Stallings RL, Nair P, Maris JM, Catchpoole D, McDermott M, O’Meara A,
Breatnach F: High-resolution analysis of chromosomal breakpoints and
genomic instability identifies PTPRD as a candidate tumor suppressor
gene in neuroblastoma. Cancer Res 2006, 66:3673-3680.
6. Veeriah S, Brennan C, Meng S, Singh B, Fagin JA, Solit DB, Paty PB, Rohle D,
Vivanco I, Chmielecki J, et al: The tyrosine phosphatase PTPRD is a tumor
suppressor that is frequently inactivated and mutated in glioblastoma
and other human cancers. Proc Natl Acad Sci USA 2009, 106:9435-9440.
7. Zhao X, Weir BA, LaFramboise T, Lin M, Beroukhim R, Garraway L,
Beheshti J, Lee JC, Naoki K, Richards WG, et al: Homozygous deletions and
chromosome amplifications in human lung carcinomas revealed by
single nucleotide polymorphism array analysis. Cancer Res 2005,
65:5561-5570.
8. Stark M, Hayward N: Genome-wide loss of heterozygosity and copy
number analysis in melanoma using high-density single-nucleotide
polymorphism arrays. Cancer Res 2007, 67:2632-2642.
9. Kohno T, Otsuka A, Girard L, Sato M, Iwakawa R, Ogiwara H, Sanchez-
Cespedes M, Minna JD, Yokota J: A catalog of genes homozygously
deleted in human lung cancer and the candidacy of PTPRD as a tumor
suppressor gene. Genes Chromosomes Cancer 2010, 49:342-352.
10. Nair P, De Preter K, Vandesompele J, Speleman F, Stallings RL: Aberrant
splicing of the PTPRD gene mimics microdeletions identified at this
locus in neuroblastomas. Genes Chromosomes Cancer 2008, 47:197-202.
11. Solomon DA, Kim JS, Cronin JC, Sibenaller Z, Ryken T, Rosenberg SA,
Ressom H, Jean W, Bigner D, Yan H, et al: Mutational inactivation of
PTPRD in glioblastoma multiforme and malignant melanoma. Cancer Res
2008, 68:10300-10306.
12. Mokarram P, Kumar K, Brim H, Naghibalhossaini F, Saberi-firoozi M,
Nouraie M, Green R, Lee E, Smoot DT, Ashktorab H: Distinct high-profile
methylated genes in colorectal cancer. PLoS One 2009, 4:e7012.
13. Brodeur GM: Neuroblastoma: biological insights into a clinical enigma.
Nat Rev Cancer 2003, 3:203-216.
14. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY,
Hammond D: Association of multiple copies of the N-myc oncogene
with rapid progression of neuroblastomas. N Engl J Med 1985,
313:1111-1116.
15. Shang X, Burlingame SM, Okcu MF, Ge N, Russell HV, Egler RA, David RD,
Vasudevan SA, Yang J, Nuchtern JG: Aurora A is a negative prognostic
factor and a new therapeutic target in human neuroblastoma. Mol
Cancer Ther 2009, 8:2461-2469.
16. Pulido R, Serra-Pages C, Tang M, Streuli M: The LAR/PTP delta/PTP sigma
subfamily of transmembrane protein-tyrosine-phosphatases: multiple
human LAR, PTP delta, and PTP sigma isoforms are expressed in a
tissue-specific manner and associate with the LAR-interacting protein
LIP.1. Proc Natl Acad Sci USA 1995, 92:11686-11690.
17. Woodings JA, Sharp SJ, Machesky LM: MIM-B, a putative metastasis
suppressor protein, binds to actin and to protein tyrosine phosphatase
delta. Biochem J 2003, 371:463-471.
18. Crane R, Gadea B, Littlepage L, Wu H, Ruderman JV: Aurora A, meiosis and
mitosis. Biol Cell 2004, 96:215-229.
19. Pulido R, Krueger NX, Serra-Pages C, Saito H, Streuli M: Molecular
characterization of the human transmembrane protein-tyrosine
phosphatase delta. Evidence for tissue-specific expression of alternative
human transmembrane protein-tyrosine phosphatase delta isoforms. J
Biol Chem 1995, 270:6722-6728.
20. Ferrari S, Marin O, Pagano MA, Meggio F, Hess D, El-Shemerly M,
Krystyniak A, Pinna LA: Aurora-A site specificity: a study with synthetic
peptide substrates. Biochem J 2005, 390:293-302.
21. Otto T, Horn S, Brockmann M, Eilers U, Schuttrumpf L, Popov N,
Kenney AM, Schulte JH, Beijersbergen R, Christiansen H, et al: Stabilization
of N-Myc is a critical function of Aurora A in human neuroblastoma.
Cancer Cell 2009, 15:67-78.
22. Ohashi S, Sakashita G, Ban R, Nagasawa M, Matsuzaki H, Murata Y,
Taniguchi H, Shima H, Furukawa K, Urano T: Phospho-regulation of human
protein kinase Aurora-A: analysis using anti-phospho-Thr288 monoclonal
antibodies. Oncogene 2006, 25:7691-7702.
23. Kitajima S, Kudo Y, Ogawa I, Tatsuka M, Kawai H, Pagano M, Takata T:
Constitutive phosphorylation of aurora-a on ser51 induces its
stabilization and consequent overexpression in cancer. PLoS One 2007, 2:
e944.
24. Murphy DM, Buckley PG, Bryan K, Das S, Alcock L, Foley NH, Prenter S,
Bray I, Watters KM, Higgins D, Stallings RL: Global MYCN transcription
factor binding analysis in neuroblastoma reveals association with
distinct E-box motifs and regions of DNA hypermethylation. PLoS One
2009, 4:e8154.
25. Murphy DM, Buckley PG, Bryan K, Watters KM, Koster J, van Sluis P,
Molenaar J, Versteeg R, Stallings RL: Dissection of the oncogenic MYCN
transcriptional network reveals a large set of clinically relevant cell cycle
genes as drivers of neuroblastoma tumorigenesis. Mol Carcinog 2011,
50:403-411.
26. van der Vaart B, Manatschal C, Grigoriev I, Olieric V, Gouveia SM, Bjelic S,
Demmers J, Vorobjev I, Hoogenraad CC, Steinmetz MO, Akhmanova A:
SLAIN2 links microtubule plus end-tracking proteins and controls
microtubule growth in interphase. J Cell Biol 2011, 193:1083-1099.
27. Ferrari S: Protein kinases controlling the onset of mitosis. Cell Mol Life Sci
2006, 63:781-795.
28. Lens SM, Voest EE, Medema RH: Shared and separate functions of polo-
like kinases and aurora kinases in cancer. Nat Rev Cancer 2010,
10:825-841.
29. Macurek L, Lindqvist A, Lim D, Lampson MA, Klompmaker R, Freire R,
Clouin C, Taylor SS, Yaffe MB, Medema RH: Polo-like kinase-1 is activated
by aurora A to promote checkpoint recovery. Nature 2008, 455:119-123.
30. Ackermann S, Goeser F, Schulte JH, Schramm A, Ehemann V, Hero B,
Eggert A, Berthold F, Fischer M: Polo-like kinase 1 is a therapeutic target
in high-risk neuroblastoma. Clin Cancer Res 2011, 17:731-741.
31. Maris JM, Morton CL, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST,
Reynolds CP, Kang MH, Wu J, et al: Initial testing of the aurora kinase A
inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).
Pediatr Blood Cancer 2010, 55:26-34.
32. Carol H, Boehm I, Reynolds CP, Kang MH, Maris JM, Morton CL, Gorlick R,
Kolb EA, Keir ST, Wu J, et al: Efficacy and pharmacokinetic/
pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237
Meehan et al. Molecular Cancer 2012, 11:6
http://www.molecular-cancer.com/content/11/1/6
Page 8 of 9
against preclinical models of pediatric cancer. Cancer Chemother
Pharmacol 2011, 68:1291-1304.
doi:10.1186/1476-4598-11-6
Cite this article as: Meehan et al.: Protein tyrosine phosphatase receptor
delta acts as a neuroblastoma tumor suppressor by destabilizing the
aurora kinase a oncogene. Molecular Cancer 2012 11:6.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Meehan et al. Molecular Cancer 2012, 11:6
http://www.molecular-cancer.com/content/11/1/6
Page 9 of 9
